Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.57 |
| ▸ | MB | P02144 | 1/20 | 0.57 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.57 |
| ▸ | CA3 | P07451 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6516221 | 0.83 | KMT2A (0.73) | KMT2AMEN1TDP1LMNACYP1A2 | |
| SCHEMBL20769833 | 0.82 | KMT2A (0.79) | KMT2AMEN1TDP1LMNACYP1A2 | |
| SCHEMBL861674 | 0.82 | SMN1; SMN2 (0.84) | KMT2AMEN1TDP1SMN1; SMN2HTT | |
| SCHEMBL171415 | 0.81 | SMN1; SMN2 (0.73) | KMT2AMEN1TDP1LMNACYP1A2 | |
| SCHEMBL14808444 | 0.81 | KMT2A (1.00) | KMT2AMEN1TDP1LMNACYP1A2 | |
| SCHEMBL15887274 | 0.79 | KMT2A (0.68) | KMT2AMEN1TDP1LMNACYP1A2 | |
| Diacetamate SCHEMBL863106 | 0.79 | KMT2A (0.81) | KMT2AMEN1TDP1LMNACYP1A2 | |
| SCHEMBL22765830 | 0.79 | KMT2A (0.68) | KMT2AMEN1TDP1LMNACYP1A2 | |
| SCHEMBL5612835 | 0.79 | KMT2A (0.61) | KMT2AMEN1TDP1LMNACYP1A2 | |
| SCHEMBL1064813 | 0.79 | KMT2A (0.71) | KMT2AMEN1TDP1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207411-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | SEAPORT THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-11883497-B2 | Lymphatic system-directing lipid prodrugs | PURETECH LYT, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| EP-4306524-A2 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | PureTech LYT, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20220001015-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | SEAPORT THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11021498-B2 | Water-soluble acetaminophen analogs | ACORDA THERAPEUTICS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| US-10442826-B2 | Water-soluble acetaminophen analogs | ACORDA THERAPEUTICS, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190092795-A1 | WATER-SOLUBLE ACETAMINOPHEN ANALOGS | NEUROGESX, INC. | 2019-03-28 | — | — | US | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-9981998-B2 | Water-soluble acetaminophen analogs | ACORDA THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| EP-2291348-A1 | WATER-SOLUBLE ACETAMINOPHEN ANALOGS | Neurogesx, Inc. (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | MSD K.K. (JP) | 2010-08-19 | — | — | US | disclosed |
| WO-2009143295-A1 | WATER-SOLUBLE ACETAMINOPHEN ANALOGS | NEUROGESX, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-7595316-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-29 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1642898-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
| EP-0276124-B1 | PROSTAGLANDIN DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | Sankyo Company Limited (JP) | 1992-05-20 | — | — | EP | disclosed |
| US-4981872-A | ANTIULCER | SANKYO COMPANY LIMITED (JP) | 1991-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220001015-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | LIPA, MALT1, SGMS1 | KMT2A 2872/4885MEN1 1498/4885TDP1 1025/4885 |
| US-10442826-B2 | Water-soluble acetaminophen analogs | PTGS1, HPGD, PYGL | KMT2A 4336/4885MEN1 4365/4885TDP1 2279/4885 |
| US-11021498-B2 | Water-soluble acetaminophen analogs | PTGS1, HPGD, PYGL | KMT2A 4336/4885MEN1 4365/4885TDP1 2279/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | KMT2A 3324/4885MEN1 4525/4885TDP1 4548/4885 |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | HRH3, HRH4, HCRTR2 | KMT2A 423/4885MEN1 1981/4885TDP1 4743/4885 |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | HRH3, HRH4, HRH2 | KMT2A 552/4885MEN1 1602/4885TDP1 4726/4885 |
| US-20190092795-A1 | WATER-SOLUBLE ACETAMINOPHEN ANALOGS | PTGS1, HPGD, PYGL | KMT2A 4336/4885MEN1 4365/4885TDP1 2279/4885 |
| US-11883497-B2 | Lymphatic system-directing lipid prodrugs | LIPA, MALT1, SGMS1 | KMT2A 2872/4885MEN1 1498/4885TDP1 1025/4885 |
| US-20240207411-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | LIPA, MALT1, SGMS1 | KMT2A 2872/4885MEN1 1498/4885TDP1 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.